AKTX
Akari Therapeutics PLCNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$20.91M
P/E Ratio
0.00
EPS
$0.00
Beta
0.65
52W High
$56.80
52W Low
$3.02
50-Day MA
$5.46
200-Day MA
$17.98
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About Akari Therapeutics PLC
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. The company is headquartered in London, the United Kingdom.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-12.08M |
| Operating Margin | 0.00% |
| Return on Equity | -155.30% |
| Return on Assets | -18.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $12.56 |
| Price-to-Book | 0.74 |
| Price-to-Sales (TTM) | 478368.50 |
| EV/Revenue | 400346.36 |
| EV/EBITDA | -0.06 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $1.14M |
| Float | $40.76B |
| % Insiders | 24.56% |
| % Institutions | 5.93% |
Historical Volatility
HV 10-Day
147.05%
HV 20-Day
123.30%
HV 30-Day
133.59%
HV 60-Day
126.50%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($26.78 target)
2
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026